MicroPort® Participates in CIT 2022 and Hosts Joint Satellite Session

Beijing, China, 30 June 2022 — MicroPort Scientific Corporation (“MicroPort®”), together with its subsidiaries Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort® Coronary”) and MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”), recently participated in the 20th Chinese Interventional Therapeutic Congress (CIT 2022), an online conference hosted by the Chinese Medical Association bringing together leading experts in the field of interventional cardiology. MicroPort® organized a joint satellite session to showcase multiple lines of business.

Prof. Alexandra Lansky from Yale University School of Medicine, chaired the satellite session. Ten renowned experts from seven countries, including Prof. Kang Jee Hoon from Korea Seoul National University Hospital, Prof. Aaron Wong from Singapore National Heart Center, Prof. Kadriye Kılıçkesmez from Turkey Cemil Tascıoglu City Hospital, and Prof. Gustavo Samaja from Buenos Aires Policlinico Bancario, Argentina, served as the panelists. Prof. Chenguang Li from Zhongshan Hospital of Fudan University and Prof. Rutao Wang from Xijing Hospital served as guest interpreters.

Prof. Giuseppe Tarantini from the University of Padua, first presented the progress of the TARGET clinical trial, a global clinical trial series on the Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk® stent”). He commented: “Firehawk® stent features the unique in-groove coating technology and the lowest drug load in the industry. Its safety and efficacy over the long term have been demonstrated in the large-scale clinical study ‘TARGET All Comers’ as well as in various studies in high-risk populations. In addition, several ongoing clinical trials in China, the US and Europe will further validate the efficacy of Firehawk® stent in combination with shorter dual antiplatelet therapy.”

Prof. Bo Xu of Fuwai Hospital of the Chinese Academy of Medical Sciences then presented the clinical follow-ups of the two-year FUTURE II trial, a pivotal study of the Firesorb® Bioresorbable Rapamycin Targeted Eluting Coronary Scaffold System ("Firesorb®"), a second-generation bioresorbable vascular stent system independently developed by MicroPort®. No significant difference was found between the two groups in the incidence of target lesion failure (TLF, 3.8% vs. 3.2%, p=0.76) and the ischemia-driven target lesion revascularization (ID-TLR, 2.4% vs. 2.8%, P = 0.78). The patient-oriented composite endpoints (PoCE, defined as all-cause death, myocardial infarction, and unplanned revascularization) at 2-year follow-up were similar (11.3% vs. 11.6%, p=0.93). In addition, no significant difference was found in the components of clinical composite endpoints, and no device-related thrombotic events occurred in either group. The 1-year landmark analysis showed no significant difference in the TLF from 1 to 2 years between the two groups (2.8% vs. 1.4%, P = 0.30), and the incidence of PoCE was similar (7.1% vs. 7.4%, P = 0.90). In addition, according to the landmark analysis of Firesorb® from 1 to 2 years, no late catch-up phenomenon was found for either TLF or PoCE. Prof. Bo Xucommented: “The promising two-year clinical result of FUTURE II will certainly reinforce the expectation for biodegradable devices.”

Prof. Ling Tao from Xijing Hospital shared a presentation on the quantitative aortography assessment of aortic regurgitation in patients with the VitaFlow® Transcatheter Aortic Valve System (“VitaFlow®”) versus other self-expanding aortic valve systems. Prof. Tao concluded: “Compared to those using other self-expanding valves, patients using VitaFlow® have a lower postoperative incidence of moderate-to-severe aortic regurgitation because of its dual-layer PET skirt design. VitaFlow® is a new self-expanding transcatheter aortic valve system developed by CardioFlow Medtech. The valve prosthesis features a hybrid density stent, a calcification-resistant treated bovine pericardium, and a double-layer skirt. Its delivery system is equipped with the world's only motorized handle. It provides a significant improvement in all aspects of performance and can better benefit the patients with aortic valve diseases.”

“Through robust clinical trials, the Firehawk® stent, the Firesorb® stent, and the VitaFlow® valve are all proving to the world how the extraordinary technology of MicroPort® products will empower patients and physicians with more choices and information” commented Prof. Bo Xu in the satellite session, “when developing products, MicroPort® focuses on scientific evaluation and relies on clinical medicine methodologies and randomized studies. We look forward to MicroPort®’s smart products going global and benefiting more patients.”

About Shanghai MicroPort Medical (Group) Co., Ltd.

Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicoPort® will continue to steadily promote the target global clinical research program, enrich the cardiovascular interventional therapy product line with the support of accumulated clinical research data, and provide patients with more high-quality and inclusive integrated solutions.

About CardioFlow Medtech Corporation

Founded in Shanghai in 2015, MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”, stock code: 02160.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is a leading medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart disease. the Company’s self-developed second-generation Transcatheter Aortic Valve Implantation (TAVI) product VitaFlow Liberty™ is the world’s only commercialized motorized retrievable system. In addition to the TAVI products, the Company has also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies, surgical valve products and surgical accessories via independent development and collaboration with global partners. At CardioFlow Metech, we strive to provide integrated therapeutic solutions for patients with heart valve disease, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at www.cardioflowmedtech.com.